The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Growth Is Projected For The Psoriasis Biosimilars Market During The Forecast Period 2026–2030?
The psoriasis biosimilars market size has experienced rapid expansion in recent years. It is anticipated to increase from $8.16 billion in 2025 to $9.08 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 11.3%. The market’s historic growth can be attributed to factors such as the high cost of reference biologics, limited patient access to treatment, the growing prevalence of moderate to severe psoriasis, increasing physician awareness and prescriptions, and initial approvals of TNF-alpha inhibitors.
The psoriasis biosimilars market is anticipated to undergo significant expansion in the upcoming years. Its valuation is expected to reach $13.79 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.0%. This growth throughout the forecast period can be attributed to the launch of new biosimilars for infliximab, etanercept, and adalimumab, the expansion of hospital and online pharmacy networks, increasing healthcare expenditure on dermatology, the rising adoption of patient assistance programs, and a growth in clinical trials for novel biosimilars. Prominent trends for this period include the increasing adoption of cost-effective psoriasis biosimilars, an elevated focus on patient access and affordability, the development of subcutaneous and intravenous administration routes, the broadening of hospital and retail pharmacy distribution channels, and the creation of targeted therapies for different types of psoriasis.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27399&type=smp
Which Economic Or Industry Drivers Are Impacting The Psoriasis Biosimilars Market?
The increasing psoriatic arthritis diagnosis rates are anticipated to propel the growth of the psoriasis biosimilars market going forward. Psoriatic arthritis is a chronic autoimmune condition involving inflammation in the joints and skin, often observed in individuals with a history of psoriasis. The rates of psoriatic arthritis diagnoses are on the rise, particularly due to improved screening protocols among individuals with psoriasis, which facilitate earlier and more accurate detection by pinpointing subtle joint symptoms that might have previously gone unnoticed. Psoriasis biosimilars aid in managing psoriatic arthritis by providing affordable alternatives to biologic therapies, effectively reducing joint inflammation and skin symptoms. For instance, in August 2025, according to the National Psoriasis Foundation (NPF), a US-based non-profit patient advocacy organization, psoriatic arthritis affects roughly 1 in 3 people living with psoriasis, and as many as 2.4 million Americans live with psoriatic arthritis, while more than 15% of people with psoriasis may also have undiagnosed psoriatic arthritis, highlighting both increasing recognition and persistent underdiagnosis of the condition. Therefore, the escalating psoriatic arthritis diagnosis rates are driving the growth of the psoriasis biosimilars market.
What Market Segments Are Evaluated Within The Psoriasis Biosimilars Market?
The psoriasis biosimilars market covered in this report is segmented –
1) By Drug Class: TNF-Alpha Inhibitors, Infliximab, Etanercept, Adalimumab, Other Biosimilars
2) By Disease Type: Plaque Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis
3) By Route Of Administration: Subcutaneous, Intravenous, Oral, Topical
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By TNF-Alpha Inhibitors: Monoclonal Antibody Biosimilars, Fusion Protein Biosimilars
2) By Infliximab: Remicade Biosimilars, CT-P13 Biosimilars
3) By Etanercept: Enbrel Biosimilars, SB4 Biosimilars
4) By Adalimumab: Humira Biosimilars, ABP 501 Biosimilars
5) By Other Biosimilars: Ustekinumab Biosimilars, Secukinumab Biosimilars
What Industry Trends Are Redefining The Psoriasis Biosimilars Market?
Companies operating within the psoriasis biosimilars market are increasingly concentrating on introducing innovative solutions, such as biosimilars specifically for plaque psoriasis, with the goal of improving treatment accessibility, lowering healthcare expenditures, and enhancing patient outcomes. These biosimilars for plaque psoriasis offer more affordable, highly comparable alternatives to established biologic drugs used to manage the chronic autoimmune skin condition characterized by red, scaly patches. For instance, in May 2025, Sandoz Group AG, a Switzerland-based company focused on generic pharmaceuticals and biosimilars, launched the Pyzchiva autoinjector, marking it as the first commercially available ustekinumab biosimilar autoinjector. Pyzchiva is approved for the treatment of adults with plaque psoriasis, psoriatic arthritis, and Crohn’s disease, as well as pediatric patients aged six years and older (weighing over 60 kg) with plaque psoriasis. This autoinjector, designed to boost patient adherence and quality of life, includes features like accurate automatic dosing, reduced injection pain, a compact design, and flexible storage options to facilitate more comfortable self-administration.
Who Are The Top Market Participants Influencing The Psoriasis Biosimilars Market?
Major companies operating in the psoriasis biosimilars market are Pfizer Inc., Amgen Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Samsung Bioepis Co. Ltd., Zydus Lifesciences Ltd., Celltrion Inc., Bio-Thera Solutions Ltd., Coherus BioSciences Inc., mAbxience S.A., Alvotech hf.
Read the full psoriasis biosimilars market report here:
https://www.thebusinessresearchcompany.com/report/psoriasis-biosimilars-global-market-report
What Are The Top-Performing Regions Within The Psoriasis Biosimilars Market?
North America was the largest region in the psoriasis biosimilars market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psoriasis biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Psoriasis Biosimilars Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=27399&type=smp
Browse Through More Reports Similar to the Global Psoriasis Biosimilars Market 2026, By The Business Research Company
Connected Rail Market Report 2026
https://www.thebusinessresearchcompany.com/report/connected-rail-global-market-report
Rail Road Construction Market Report 2026
https://www.thebusinessresearchcompany.com/report/rail-road-construction-global-market-report
Freight Railcar Parts Market Report 2026
https://www.thebusinessresearchcompany.com/report/freight-railcar-parts-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model